Heather Mary Ellen Duggan

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Kudos Pharmaceuticals Limited, Astrazeneca Ab, Other. Active years: 2011-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heather Mary Ellen Duggan. Retrieved from https://idiyas.com/inventor/heather-mary-ellen-duggan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 19(Granted Patents)

Location History:

Horsham, GB (2011)
Macclesfield, GB (2012 - 2018)

Company Filing History:

4 out of 36

Kudos Pharmaceuticals Limited

1 out of 834,601

Other

patents

Years Active: 2011-2018

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10034884 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors (2018-07-31),

2. 9717736 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors (2017-08-01),

3. 9102670 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors (2015-08-11),

4. 8435985 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors (2013-05-07),

5. 8101602 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors (2012-01-24),

6. 7902189 - Compounds (2011-03-08),

Title: Heather Mary Ellen Duggan: Innovator in mTOR Inhibitors

Introduction

Heather Mary Ellen Duggan is a prominent inventor based in Macclesfield, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of mTOR inhibitors. With a total of six patents to her name, her work has the potential to impact cancer treatment significantly.

Latest Patents

Among her latest patents, Duggan has developed pyrido-, pyrazo-, and pyrimido-pyrimidine derivatives as mTOR inhibitors. These compounds are designed to serve as medicaments in the treatment of cancer. The patents detail processes for the manufacture of these compounds, as well as their use in therapeutic applications.

Career Highlights

Duggan has worked with notable companies in the pharmaceutical industry, including Kudos Pharmaceuticals Limited and AstraZeneca. Her experience in these organizations has allowed her to refine her expertise and contribute to groundbreaking research.

Collaborations

Throughout her career, Duggan has collaborated with esteemed colleagues such as Keith Allan Menear and Graeme Cameron Murray Smith. These partnerships have fostered innovation and have been instrumental in her research endeavors.

Conclusion

Heather Mary Ellen Duggan is a distinguished inventor whose work in mTOR inhibitors holds promise for advancing cancer treatment. Her contributions to the pharmaceutical field are noteworthy and continue to inspire future innovations.

Profile summary based on public USPTO records.